Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimavanserin for negative symptoms of schizophrenia
NCT02970305Phase 2Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Nov 2016
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing Pimavanserin with Placebo (2 arms). Primary endpoint: Negative Symptom Assessment-16 Total Score at 26 weeks. Started Nov 2016; status: completed.
02
Drugs
pimavanserin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02970305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02970305.